Service de Pharmacologie Médicale et Clinique, Centre de PharmacoVigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament, Faculté de Médecine, Centre Hospitalier Universitaire, 37 allées Jules-Guesde, 31000, Toulouse, France.
INTHERES, Université de Toulouse, INRA, ENVT, Toulouse, France.
Drug Saf. 2020 Jul;43(7):657-660. doi: 10.1007/s40264-020-00955-y.
Hydroxychloroquine was recently promoted in patients infected with COVID-19 infection. A recent experimental study has suggested an increased toxicity of hydroxychloroquine in association with metformin in mice.
The present study was undertaken to investigate the reality of this putative drug-drug interaction between hydroxychloroquine and metformin using pharmacovigilance data.
Using VigiBase, the WHO pharmacovigilance database, we performed a disproportionality analysis (case/non-case study). Cases were reports of fatal outcomes with the drugs of interest and non-cases were all other reports for these drugs registered between 1 January 2000 and 31 December 2019. Data with hydroxychloroquine (or metformin) alone were compared with the association hydroxychloroquine + metformin. Results are reported as ROR (reporting odds ratio) with their 95% confidence interval.
Of the 10,771 Individual Case Safety Reports (ICSR) involving hydroxychloroquine, 52 were recorded as 'fatal outcomes'. In comparison with hydroxychloroquine alone, hydroxychloroquine + metformin was associated with an ROR value of 57.7 (23.9-139.3). In comparison with metformin alone, hydroxychloroquine + metformin was associated with an ROR value of 6.0 (2.6-13.8).
Our study identified a signal for the association hydroxychloroquine + metformin that appears to be more at risk of fatal outcomes (particularly by completed suicides) than one of the two drugs when given alone.
羟氯喹最近在感染 COVID-19 的患者中得到推广。最近的一项实验研究表明,在小鼠中羟氯喹与二甲双胍联合使用会增加毒性。
本研究旨在利用药物警戒数据调查羟氯喹和二甲双胍之间这种潜在药物-药物相互作用的现实情况。
使用世界卫生组织药物警戒数据库 VigiBase,我们进行了一项比例失调分析(病例/非病例研究)。病例是指与研究药物相关的致命结局报告,而非病例是指这些药物在 2000 年 1 月 1 日至 2019 年 12 月 31 日期间注册的所有其他报告。将羟氯喹(或二甲双胍)单药组的数据与羟氯喹+二甲双胍联合用药组的数据进行比较。结果以报告比值比(报告比值比)及其 95%置信区间表示。
在涉及羟氯喹的 10771 份个体病例安全报告(ICSR)中,有 52 份记录为“致命结局”。与羟氯喹单药组相比,羟氯喹+二甲双胍组的 ROR 值为 57.7(23.9-139.3)。与二甲双胍单药组相比,羟氯喹+二甲双胍组的 ROR 值为 6.0(2.6-13.8)。
我们的研究发现了羟氯喹+二甲双胍联合用药的信号,与两种药物单独使用相比,该联合用药似乎更有发生致命结局(特别是自杀死亡)的风险。